The New England journal of medicine, 2020-11, Vol.383 (19), p.1813-1826
- Beigel, John H
- Tomashek, Kay M
- Dodd, Lori E
- Mehta, Aneesh K
- Zingman, Barry S
- Kalil, Andre C
- Hohmann, Elizabeth
- Chu, Helen Y
- Luetkemeyer, Annie
- Kline, Susan
- Lopez de Castilla, Diego
- Finberg, Robert W
- Dierberg, Kerry
- Tapson, Victor
- Hsieh, Lanny
- Patterson, Thomas F
- Paredes, Roger
- Sweeney, Daniel A
- Short, William R
- Touloumi, Giota
- Lye, David Chien
- Ohmagari, Norio
- Oh, Myoung-don
- Ruiz-Palacios, Guillermo M
- Benfield, Thomas
- Fätkenheuer, Gerd
- Kortepeter, Mark G
- Atmar, Robert L
- Creech, C. Buddy
- Lundgren, Jens
- Babiker, Abdel G
- Pett, Sarah
- Neaton, James D
- Burgess, Timothy H
- Bonnett, Tyler
- Green, Michelle
- Makowski, Mat
- Osinusi, Anu
- Nayak, Seema
- Lane, H. Clifford
2020
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Beigel, John H
- Tomashek, Kay M
- Dodd, Lori E
- Mehta, Aneesh K
- Zingman, Barry S
- Kalil, Andre C
- Hohmann, Elizabeth
- Chu, Helen Y
- Luetkemeyer, Annie
- Kline, Susan
- Lopez de Castilla, Diego
- Finberg, Robert W
- Dierberg, Kerry
- Tapson, Victor
- Hsieh, Lanny
- Patterson, Thomas F
- Paredes, Roger
- Sweeney, Daniel A
- Short, William R
- Touloumi, Giota
- Lye, David Chien
- Ohmagari, Norio
- Oh, Myoung-don
- Ruiz-Palacios, Guillermo M
- Benfield, Thomas
- Fätkenheuer, Gerd
- Kortepeter, Mark G
- Atmar, Robert L
- Creech, C. Buddy
- Lundgren, Jens
- Babiker, Abdel G
- Pett, Sarah
- Neaton, James D
- Burgess, Timothy H
- Bonnett, Tyler
- Green, Michelle
- Makowski, Mat
- Osinusi, Anu
- Nayak, Seema
- Lane, H. Clifford
- Titel
- Remdesivir for the Treatment of Covid-19 — Final Report
- Ist Teil von
- The New England journal of medicine, 2020-11, Vol.383 (19), p.1813-1826
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2020
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- In this randomized, double-blind trial in 1062 adults hospitalized with Covid-19, remdesivir was superior to placebo in shortening the time to recovery (10 days, vs. 15 days with placebo). The estimates of mortality by day 29 were 11.4% with remdesivir and 15.2% with placebo. The benefit of remdesivir was most apparent in patients who were receiving low-flow oxygen at baseline.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2007764Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7262788
- Format
- –
- Schlagworte
- Adenosine Monophosphate - administration & dosage, Adenosine Monophosphate - adverse effects, Adenosine Monophosphate - analogs & derivatives, Adenosine Monophosphate - therapeutic use, Administration, Intravenous, Adult, Aged, Alanine - administration & dosage, Alanine - adverse effects, Alanine - analogs & derivatives, Alanine - therapeutic use, Allergies, Antiviral agents, Antiviral Agents - administration & dosage, Antiviral Agents - adverse effects, Antiviral Agents - therapeutic use, Antiviral drugs, Betacoronavirus, Clinical trials, Consent, Coronavirus Infections - drug therapy, Coronavirus Infections - mortality, Coronavirus Infections - therapy, Coronaviruses, COVID-19, COVID-19 Drug Treatment, Disease, Double-Blind Method, Drug dosages, Extracorporeal Membrane Oxygenation, Female, Hospitalization, Hospitals, Humans, Infectious diseases, Intravenous administration, Kaplan-Meier Estimate, Laboratories, Male, Middle Aged, Middle East respiratory syndrome, Mortality, Original, Oxygen Inhalation Therapy, Pandemics, Patients, Pneumonia, Viral - drug therapy, Pneumonia, Viral - mortality, Pneumonia, Viral - therapy, Respiration, Artificial, Respiratory diseases, Respiratory tract diseases, RNA polymerase, SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2, Statistical analysis, Time Factors, Young Adult